Janney Montgomery Scott Analysts Give Collegium Pharmaceutical (COLL) a $26.00 Price Target

Janney Montgomery Scott set a $26.00 price target on Collegium Pharmaceutical (NASDAQ:COLL) in a research note released on Tuesday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

COLL has been the topic of a number of other reports. Zacks Investment Research raised shares of Collegium Pharmaceutical from a hold rating to a buy rating and set a $16.00 price target on the stock in a report on Monday, November 13th. HC Wainwright restated a buy rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, November 8th. BidaskClub upgraded Collegium Pharmaceutical from a buy rating to a strong-buy rating in a research note on Friday, December 29th. Piper Jaffray Companies set a $19.00 price objective on Collegium Pharmaceutical and gave the company a buy rating in a research note on Wednesday, November 29th. Finally, Needham & Company LLC boosted their price objective on Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a buy rating in a research note on Tuesday, December 5th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $26.33.

Collegium Pharmaceutical (NASDAQ COLL) opened at $21.00 on Tuesday. The firm has a market cap of $697.81, a PE ratio of -7.05 and a beta of 0.80. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $26.77.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.28. The company had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.13) EPS. analysts anticipate that Collegium Pharmaceutical will post -2.5 EPS for the current year.

In related news, CTO Alison B. Fleming sold 4,029 shares of the business’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $17.00, for a total value of $68,493.00. Following the sale, the chief technology officer now directly owns 28,513 shares in the company, valued at approximately $484,721. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Michael Thomas Heffernan sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total value of $500,200.00. Following the completion of the sale, the chairman now owns 535,395 shares in the company, valued at $13,390,228.95. The disclosure for this sale can be found here. Insiders sold a total of 1,105,558 shares of company stock worth $19,346,677 over the last 90 days. 25.76% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors raised its stake in Collegium Pharmaceutical by 27.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after acquiring an additional 2,802 shares during the period. Royal Bank of Canada increased its position in shares of Collegium Pharmaceutical by 12.7% during the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 3,285 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in shares of Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 3,500 shares during the period. Teton Advisors Inc. increased its position in shares of Collegium Pharmaceutical by 18.5% during the fourth quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock valued at $591,000 after buying an additional 5,000 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of Collegium Pharmaceutical by 12.8% during the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after buying an additional 5,136 shares during the period. Institutional investors and hedge funds own 82.29% of the company’s stock.

WARNING: “Janney Montgomery Scott Analysts Give Collegium Pharmaceutical (COLL) a $26.00 Price Target” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.com-unik.info/2018/02/09/janney-montgomery-scott-analysts-give-collegium-pharmaceutical-coll-a-26-00-price-target.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit